Adagio Therapeutics Appoints Senior Pharmaceutical Industry and Regulatory Executives to Board of Directors
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions to treat infectious diseases with pandemic potential, today announced the expansion of the board of directors of the company with key appointments including:
Tom Heyman, Former Chairman of the Johnson & Johnson Development Corporation (JJDC)
Anand Shah, DM, former Deputy Commissioner for Medical and Scientific Affairs at the United States Food and Drug Administration (FDA).
Michael Wyzga, President of MSW Consulting, Inc.
“I am very happy to welcome Tom, Anand and Mike to our board of directors; they bring us unparalleled expertise gained through their respective roles in the industry, and join us at a critical time as we prepare for the potential commercialization of ADG20 to combat COVID-19, particularly the variants that are emerging rapidly, ”said René Russo, Adagio co-founder and chairman of the board. “During his 37 year career with Johnson & Johnson, Tom has held a wide range of leadership roles in R&D, business development, corporate strategy and capital investment. Deputy Commissioner of the FDA until January 2021, Anand led the development of a consensus medical and scientific policy and, since the COVID-19 pandemic, he has worked in the federal government and collaborated with the private sector to accelerate the development of vaccines and treatments ”.
Jane Henderson, Chief Financial Officer at Adagio, added, “As we ramp up various clinical trials with ADG20, financial strength and discipline are paramount to our success. We are very happy to welcome Mike to our board; he brings us years of experience as director of exceptional financial operations in public and private companies in the pharmaceutical industry. We look forward to partnering with him, as well as Tom and Anand, and benefiting from their invaluable knowledge in clinical development, financial best practices, regulatory strategy, policy engagement and business strategy execution. , which will allow us to tackle this global pandemic today ”.
Tom Heyman has extensive experience in the biopharmaceutical industry, particularly in the area of business development and venture capital. He most recently served as chairman of JJDC, Johnson & Johnson’s venture capital group, where he managed approximately $ 1.5 billion in capital and oversaw investments in more than 120 companies. Prior to joining JJDC, Mr. Heyman led the business development of Johnson & Johnson’s pharmaceutical group, Janssen for 23 years, participating in hundreds of licensing and M&A negotiations. Under his leadership, major licensing negotiations were carried out for products such as Levaquin, Aciphex, Incivo, Olysio, Velcade, Invokana, Imbruvica, Xarelto and Darzalex, many of these products reaching sales exceeding $ 1 billion annually. . During his tenure, he also led a major restructuring within Janssen Belgium and implemented a new strategic plan for the site focused mainly on external innovation and value creation. Mr. Heyman holds a Master of Laws degree from KU Leuven, Belgium. He pursued postgraduate studies in international law in Geneva, Switzerland, and postgraduate studies in business management at the University of Antwerp, Belgium.
Anand Shah, DM, is a leader in health policy in the United States; he most recently served as deputy commissioner for medical and scientific affairs at the FDA. Dr Shah has been in charge of developing medical and scientific policy for high priority programs including advanced manufacturing, the coronavirus treatment acceleration program, COVID-19 vaccine development and decentralized clinical trials. Under his leadership, the FDA launched the Pandemic Preparedness and Recovery Plan (PREPP) to strengthen the COVID-19 pandemic response and resilience for future public health emergencies. Dr. Shah has represented the FDA to senior policymakers in the White House, Cabinet, Congress, and federal and local state governments. He previously held leadership positions with the Centers for Medicare & Medicaid Services, as Senior Medical Advisor and Chief Medical Officer of the Center for Medicare & Medicaid Innovation. Dr. Shah served as Chief Resident during his radiation oncology internship at Columbia University. He also holds a Doctor of Medicine degree from the University of Pennsylvania and a Diploma in Health Care Management and Policy from the Harvard School of Public Health. Dr Shah holds a degree in economics from Duke University.
Since 2013, Michael Wyzga has served as President of MSW Consulting, Inc, a private company specializing in strategic biotechnology consulting. Previously, he was President, CEO and Board Member of Radius Health, Inc. From 1993 to 2011, Mr. Wyzga held various leadership roles at Genzyme Corporation, including Executive Vice President of Finance and of chief financial officer. During his time at Genzyme, Mr. Wyzga was instrumental in the successful development and commercialization of many important therapies, including Cerezyme for Gaucher disease, Fabrazyme for Fabry disease, Renagel treating dialysis patients and Campath treating chronic lymphocytic leukemia. Mr. Wyzga has served on the boards of directors of several public companies, including Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc., X4 Pharmaceuticals, GenSight Biologics, LogicBio Therapeutics, Akebia Therapeutics, Inc., Idenix Pharmaceuticals, Inc. and Prosensa Holding BVM Wyzga obtained an MBA from Providence College and a BA from Suffolk University.
About Adagio Therapeutics
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions to treat infectious diseases with pandemic potential. Adagio’s antibody portfolio has been enhanced through the antibody engineering capabilities of industry-leading Adimab, which is designed to provide patients and clinicians with an effective combination of potency, breadth, long-lasting protection (e.g. longer half-life), ease of manufacture and affordability. Adagio’s anti-SARS-CoV-2 antibody portfolio comprises multiple, broad-spectrum, non-competing neutralizing antibodies carrying distinct binding epitopes, led by ADG20. Adagio has secured production capacity for ADG20 from third party contract manufacturers until the end of clinical trials and, if approved by regulatory authorities, until initial commercial launch. For more information, please visit the website www.adagiotx.com.
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared to the source text, which will set a precedent.
Dan Budwick, 1AB
Monique Allaire, strategic communications, THRUST
© Business Wire, Inc.
This document is not authored by AFP and AFP cannot be held responsible for its content. If you have any questions about the content, please contact the people/companies indicated in this press release.